麝香保心丸治疗冠心病心绞痛  

Clinical Trial of Shexiang Baoxin Wan on Angia Pectus

作　　者：罗雪挺[1] 胡有志[1] 冯德勋[1] 

机构地区：[1]湖北中医学院附属医院内科,武汉430061

出　　处：《血栓与止血学》2007年第5期212-215,共4页Chinese Journal of Thrombosis and Hemostasis

摘　　要：目的评价麝香保心丸治疗冠心病心绞痛的临床疗效与安全性。方法以麝香保心丸与地奥心血康胶囊对比,进行随机、阳性药对照的临床试验。结果麝香保心丸缓解冠心病心绞痛症状的有效率为92.3%,能减少心绞痛的发作次数、持续时间和程度并减少硝酸甘油的用量,治疗前后比较差异有显著性(P<0.01)。中医症侯疗效的总有效率达91.1%,治疗后各单项中医症状均有不同程度改善,其中尤以胸闷痛(有效率91.1%)、心悸(有效率88.6%)症状改善较明显。麝香保心丸心电图总有效率为60.0%,能明显减少心电图∑ST、NST、NT,治疗前后比较差异有显著性(P<0.01)。麝香保心丸改善血液流变学指标,治疗后患者的全血黏度(高切、低切)、血浆黏度、红细胞比积明显降低(P<0.01),纤维蛋白原有所下降(P>0.05)。两组均对血、尿、粪常规及肝、肾功能无不良影响,未见明显不良反应。结论麝香保心丸治疗冠心病心绞痛安全、有效。Objective Evaluate clinical effect and safety of shexiang- baoxin- wan on angina pectoris. Methods Compared shexiang- baoxin- wan with di- ao- xin- xue- kang by randomized, controlled clinical trail. Results Among allocated to shexiang- baoxin-wan, angina attack and the dose of nitroglycerin significant decreased（P 〈0.01 ）. Statistically significant difference were observed at the reduction of total efficiency of ameliorate the traditional Chinese medicine syndrome （91.1% ） , especially at chest pain （91.1% ） , palpitation （88.6%） , ECG （60.0%） . The marker of hemorheology, blood viscosity, and PCV significantly ameliorate （ P 〈 0.01 ） in shexiang- baoxin- wan group and fibrinogen tend to decrease. （ P 〉 0.05 ）, abnormality of blood , urine, stool RT did not found in the two groups. Conclusion Shexiang-baoxin-wan capsule is safe and effective to treat angina pectoris.

关 键 词：麝香保心丸 心绞痛 临床试验 

分 类 号：R541.4[医药卫生—心血管疾病]